Seeking Alpha

Covidien (COV) plans to spin off its pharma business into a standalone public company. At...

Covidien (COV) plans to spin off its pharma business into a standalone public company. At present, the pharma unit accounts for $2B of sales. Post-split, Covidien's medical products business will generate around $9.6B in sales. (PR)
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|